Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Aegis Therapeutics Launches New Website

SAN DIEGO, CA  August  7, 2013 – Aegis Therapeutics LLC is happy to announce the launching of our updated website. The new website provides expanded technology and business related information relating to the Aegis Intravail®, ProTek®, and Aegis HydrogelTM  technologies, along with some publications explaining how our technologies work and how they may be used to enhance your company’s position in the rapidly changing pharmaceutical and regulatory environments involving noninvasive drug delivery, biosimilars, bio superior’s, and next-generation innovator biotherapeutics.

The new website also provides a means for subscribers to stay current with new technology and business developments at Aegis. Subscribers will automatically receive notifications of new technological developments, issued patents, and licensing or partnering agreements.

If you are receiving this announcement, and wish to continue receiving future announcements automatically, you do not need to do anything. If you wish to unsubscribe from future announcements, please click the unsubscribe link below.

We hope you find a new website format useful, and we welcome any suggestions or comments that you would like to make as to how we may improve the usefulness of a website.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.

For more information about Aegis, please visit:  http://www.aegisthera.com.